# Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma

> **NCT01582516** · PHASE1,PHASE2 · COMPLETED · sponsor: **Erasmus Medical Center** · enrollment: 20 (actual)

## Conditions studied

- Brain Tumor
- Recurring Glioblastoma

## Interventions

- **BIOLOGICAL:** delta-24-RGD adenovirus

## Key facts

- **NCT ID:** NCT01582516
- **Lead sponsor:** Erasmus Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2014-12
- **Final completion:** 2014-12
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-03-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01582516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01582516, "Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01582516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*